Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (11-20 of 437) with videos related to

Pageof 44
Sort By:
Innere Medizin (Heidelberg, Germany)|August 4, 2022
[Immunotherapy for non-small cell lung cancer (NSCLC)]Nikolaj Frost, Martin Reck
Lung Cancer (Amsterdam, Netherlands)|November 24, 2004
Chemotherapy in stage-IV NSCLCMartin Reck, Ulrich Gatzemeier
Nature Reviews. Clinical Oncology|March 2, 2010
Targeted therapies: Thalidomide in lung cancer therapy-what have we learned?Martin Reck, Ulrich Gatzemeier
Lung Cancer (Amsterdam, Netherlands)|June 30, 2005
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinibMartin Reck, Ulrich Gatzemeier
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 26, 2024
Non-Small Cell Lung Cancer Metastatic Without Oncogenic AlterationsNikolaj Frost, Martin Reck
Onkologie|September 15, 2010
Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibitionMartin Reck, Ralf Gutzmer
Lung Cancer (Amsterdam, Netherlands)|June 27, 2008
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancerMartin Reck, Lucio Crinò
Oncology Research and Treatment|June 5, 2016
Immunotherapy for Lung CancerNiels Reinmuth, Martin Reck
Expert Review of Anticancer Therapy|May 10, 2005
Pemetrexed-cisplatin combination in mesotheliomaMartin Reck, Ulrich Gatzemeier
Onkologie|December 7, 2005
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatientsMartin Reck, Ulrich Gatzemeier
Pageof 44

Showing results (11-20 of 437) with videos related to

Sort By:
Pageof 44
Innere Medizin (Heidelberg, Germany)|August 4, 2022
[Immunotherapy for non-small cell lung cancer (NSCLC)]Nikolaj Frost, Martin Reck
Lung Cancer (Amsterdam, Netherlands)|November 24, 2004
Chemotherapy in stage-IV NSCLCMartin Reck, Ulrich Gatzemeier
Nature Reviews. Clinical Oncology|March 2, 2010
Targeted therapies: Thalidomide in lung cancer therapy-what have we learned?Martin Reck, Ulrich Gatzemeier
Lung Cancer (Amsterdam, Netherlands)|June 30, 2005
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinibMartin Reck, Ulrich Gatzemeier
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 26, 2024
Non-Small Cell Lung Cancer Metastatic Without Oncogenic AlterationsNikolaj Frost, Martin Reck
Onkologie|September 15, 2010
Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibitionMartin Reck, Ralf Gutzmer
Lung Cancer (Amsterdam, Netherlands)|June 27, 2008
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancerMartin Reck, Lucio Crinò
Oncology Research and Treatment|June 5, 2016
Immunotherapy for Lung CancerNiels Reinmuth, Martin Reck
Expert Review of Anticancer Therapy|May 10, 2005
Pemetrexed-cisplatin combination in mesotheliomaMartin Reck, Ulrich Gatzemeier
Onkologie|December 7, 2005
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatientsMartin Reck, Ulrich Gatzemeier
Pageof 44